[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100462505":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":38,"centralContacts":43,"locations":51,"responsibleParty":70,"collaborators":73,"id":82,"slug":31,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":83,"sex":89,"minAge":90,"maxAge":31,"enrollmentInfo":91,"targetDuration":31,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":31,"overallStatus":53,"whyStopped":31,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Central Hospital, Nancy, France","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Amoxicillin","EXPERIMENTAL","Each patient will receive the IV antibiotic required to treat the infection, and after the proper duration of the IV antibiotic is over, the patient will receive a few days of the oral version of the same antibiotic.",[13],"Drug: Amoxicillin",{"label":15,"type":10,"description":11,"interventionNames":16},"Ofloxacin",[17],"Drug: Ofloxacin",{"label":19,"type":10,"description":11,"interventionNames":20},"Levofloxacin",[21],"Drug: Levofloxacin",{"label":23,"type":10,"description":11,"interventionNames":24},"Sulfamethoxazole trimethoprim",[25],"Drug: Sulfamethoxazole trimethoprim",[27,32,34,36],{"type":28,"name":9,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally",[9],null,{"type":28,"name":19,"description":29,"armGroupLabels":33,"otherNames":31},[19],{"type":28,"name":15,"description":29,"armGroupLabels":35,"otherNames":31},[15],{"type":28,"name":23,"description":29,"armGroupLabels":37,"otherNames":31},[23],[39],{"name":40,"affiliation":41,"role":42},"Niasha MICHOT, MD","CHRU Nancy","PRINCIPAL_INVESTIGATOR",[44,48],{"name":40,"role":45,"phone":46,"phoneExt":31,"email":47},"CONTACT","+33383155108","n.michot@chru-nancy.fr",{"name":49,"role":45,"phone":31,"phoneExt":31,"email":50},"Elise Pape","e.pape@chru-nancy.fr",[52],{"facility":41,"status":53,"city":54,"state":55,"zip":56,"country":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"RECRUITING","Vandœuvre-lès-Nancy","Lorraine","54500","France",{"type":59,"coordinates":60},"Point",[61,62],6.17114,48.66115,{"lat":62,"lon":61},[65,66],{"name":40,"role":45,"phone":46,"phoneExt":31,"email":47},{"name":67,"role":45,"phone":68,"phoneExt":31,"email":69},"Julie LECOMTE","+33383155278","ju.lecomte@chru-nancy.fr",{"type":42,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"MICHOT Niasha","Principal Investigator",[74,76,79],{"name":75,"class":6},"Société Francophone Nutrition Clinique et Métabolisme",{"name":77,"class":78},"FIlière des Maladies rares Abdomino-THOraciques","UNKNOWN",{"name":80,"class":81},"Fresenius Kabi","INDUSTRY","100462505",false,"NCT05302531","Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome","Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome : a Monocentric Pilot Study","GRAAL","Inclusion Criteria:\n\n* Short bowel syndrome\n* Treated for a documented infection with antibiogram by amoxicillin (+\u002F- clavulanic acid)or ofloxacin or levofloxacin or sulfamethoxazole\u002Ftrimethoprim\n* Hospitalized in the Nutritional Assistant Unit or the Infectiology Unit of the Regional University Hospital of Nancy\n* Affiliated to a social security system\n* Having received an physical examination before entering study\n* Having received full information regarding the study organization and having signed the informed consent\n\nExclusion Criteria:\n\n* Patient at risk of worsening their oral absorption abilities during study\n* Patient requiring dialysis\n* Women of childbearing age without efficient birth control\n* Allergy to any of the drugs tested\n* Person concerned by Articles L. 1121-5, L. 1121-7 et L1121-8 of the Code of public health\n* Person deprived of liberty or person undergoing psychiatric care pursuant to articles L. 3212-1 et L. 3213-1","ALL","18 Years",{"count":92,"type":93},10,"ESTIMATED","INTERVENTIONAL",[96],"PHASE1","The purpose of this study is to assess the drug absorption of oral antibiotics in patients with short bowel syndrome.",[99,100],"Short Bowel Syndrome","Infection, Bacterial","2024-08-28",{"date":103,"type":104},"2024-08-29","ACTUAL",{"date":106,"type":104},"2022-12-09",{"date":108,"type":93},"2025-02",{"name":5,"class":6},1]